ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study.
about
Long-Term Outcomes with Medications for Attention-Deficit Hyperactivity DisorderAssociations of sleep disturbance with ADHD: implications for treatmentA review of long-acting medications for ADHD in CanadaMethylphenidate enhances prepulse inhibition during processing of task-relevant stimuli in attention-deficit/hyperactivity disorder.Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefits of long-acting stimulantsProgress and promise of attention-deficit hyperactivity disorder pharmacogenetics.Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder.Inhibitory functioning across ADHD subtypes: recent findings, clinical implications, and future directions.Evaluation of risks associated with short- and long-term psychostimulant therapy for treatment of ADHD in children.Attention deficit/hyperactivity disorder: pharmacotherapy.Open-label use of placebos in the treatment of ADHD: a pilot study.Using the ASEBA to Screen for Callous Unemotional Traits in Early Childhood: Factor Structure, Temporal Stability, and Utility.Parent and teacher ratings of attention during a year-long methylphenidate trial in children treated for cancerGrowth on stimulant medication; clarifying the confusion: a review.Participant satisfaction in a study of stimulant, parent training, and risperidone in children with severe physical aggression.Drug therapy of attention deficit hyperactivity disorder: current trends.New drugs for the treatment of attention-deficit/hyperactivity disorder.The safety of non-stimulant agents for the treatment of attention-deficit hyperactivity disorder.Titrating Optimal Dose of Osmotic-Controlled Release Oral Delivery (OROS)-Methylphenidate and Its Efficacy and Safety in Korean Children with ADHD: A Multisite Open Labeled StudyOsmotic, controlled-release methylphenidate for the treatment of ADHD.The pharmacogenomic era: promise for personalizing attention deficit hyperactivity disorder therapy.Effects of Methylphenidate on Sleep Functioning in Children with Attention-Deficit/Hyperactivity DisorderDiagnostic and treatment challenges of chronic fatigue syndrome: role of immediate-release methylphenidate.Improving psychostimulant adherence in children with ADHD.Safety of medicines used for ADHD in children: a review of published prospective clinical trials.A review of OROS methylphenidate (Concerta(®)) in the treatment of attention-deficit/hyperactivity disorder.Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: Meta-analysis based on head-to-head trials.Long-acting stimulants: development and dosing.Influence of methylphenidate on eating in obese men.Parent satisfaction in a multi-site acute trial of risperidone in children with autism: a social validity study.
P2860
Q22241421-ED6A31A3-0038-4826-90B1-F1A9F9E2136AQ27027062-799E590E-32F3-4E7D-88B8-FB785EC28543Q28263326-3861AD12-BC0C-42BE-AAEE-D0C1CBB45137Q30474407-DCB69FFA-E445-4E7D-A381-4BEB559576BEQ33746664-F6585457-C654-425F-B8CD-F43A2F28A0DBQ33870580-A039F1E8-A565-4C3A-B7C7-5DD4D3B9F820Q34021980-41EBBDBA-A048-4602-9444-EAC3A8790640Q34040074-BE85B87C-B35C-40FC-8796-A665CDA130CEQ34303865-B0D0FD7B-7803-40AB-AF93-D521E28D0A4CQ34418634-8AB6C319-7A65-4476-B121-1EF0B58B10CFQ34732633-7F02835E-F5B8-43E2-9BE5-3F2B805DCD3AQ34772350-294B1B4F-A2B1-4C28-9E5A-B582F645713FQ35047116-945CFFC5-ED8F-4953-95C8-D8BEA79E7869Q35284563-E89B44EE-D0BB-4885-B867-6156C3399EFBQ35483556-7B6E96D8-1640-4F39-AA56-0277839BE9CCQ35964370-A65CCC65-43E3-441E-9EDD-65EA085F9D68Q35967393-592F9B10-3B26-4DAB-807E-16B50A709392Q36082025-ABD7304D-C077-4659-B46F-1E8C9DDAE8F9Q36229931-1F3AB464-6F25-4F07-B8D9-AC08120A9DD5Q36613947-110A2863-E670-4B12-9137-F93C4D66C62BQ36699910-31038C59-8845-43DE-A2DF-A8C6253757C9Q36952114-11BAF013-852A-41F0-A931-AFCD974257FCQ37174049-92B22BC5-58D4-491B-9594-A456067AFA30Q37301222-14FE1FB4-0FA7-41AA-A72E-EAF5A88E92C6Q38205749-1B216819-9B48-4A67-BEF4-C63936BC3AB4Q38239633-AE9FD10D-B076-450C-B1A3-7AA06D26ED8EQ39040595-9BC47B70-9DB2-4288-98EF-04E4D270F4FBQ42761512-8214A15D-8947-4F32-86CA-FA4F40C45AAEQ44774930-25B962A7-7F07-4EAF-9CD4-B38226EA1CD7Q50302223-52D3881C-8A8D-4905-B252-4EBC5FA7632C
P2860
ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
ADHD treatment with once-daily ...... a long-term open-label study.
@en
ADHD treatment with once-daily ...... a long-term open-label study.
@nl
type
label
ADHD treatment with once-daily ...... a long-term open-label study.
@en
ADHD treatment with once-daily ...... a long-term open-label study.
@nl
prefLabel
ADHD treatment with once-daily ...... a long-term open-label study.
@en
ADHD treatment with once-daily ...... a long-term open-label study.
@nl
P2093
P1476
ADHD treatment with once-daily ...... a long-term open-label study.
@en
P2093
C Keith Conners
Donna Palumbo
Gerald August
Howard Abikoff
James Swanson
Keith McBurnett
Laurence Greenhill
Marc Atkins
Mark Stein
Mark Wolraich
P304
P356
10.1097/01.CHI.0000046814.95464.7D
P577
2003-04-01T00:00:00Z